First Report of Autologous Cord Blood Transplantation in the Treatment of a Child With Leukemia

Author:

Hayani Ammar1,Lampeter Eberhard23,Viswanatha David4,Morgan David5,Salvi Sharad N.1

Affiliation:

1. Sections of Pediatric Hematology/Oncology

2. VITA34 International AG, Leipzig, Germany

3. CorCell Inc, Philadelphia, Pennsylvania

4. Department of Pathology, Mayo Clinic, Rochester, Minnesota

5. Radiation Oncology, Advocate Hope Children's Hospital and Christ Medical Center, Oak Lawn, Illinois

Abstract

We present the case of a 3-year-old girl with acute lymphoblastic leukemia who developed isolated central nervous system relapse while receiving chemotherapy 10 months after diagnosis. The child achieved a second remission on retreatment with systemic and intrathecal chemotherapy. She then underwent myeloablative chemotherapy and radiation therapy followed by infusion of her own umbilical cord blood, which the parents had saved after her delivery. She is now doing well and is in complete remission 20 months after cord blood transplantation. In this first report of autologous cord blood transplantation for treatment of childhood leukemia, we discuss the safety and feasibility of this procedure as well as some of the uncertainties surrounding autologous cord blood collection and usage.

Publisher

American Academy of Pediatrics (AAP)

Subject

Pediatrics, Perinatology and Child Health

Cited by 53 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Stem Cell Therapy in Obstetrics and Gynecology;Comprehensive Hematology and Stem Cell Research;2024

2. Therapeutic Potential of Umbilical Cord Stem Cells for Liver Regeneration;Current Stem Cell Research & Therapy;2020-04-25

3. Stem Cell Transplantation in Pediatrics;Pediatric Hematopoietic Stem Cell Transplantation for Pharmacists;2020

4. Autologous Cord Blood in Children with Cerebral Palsy: A Review;International Journal of Molecular Sciences;2019-05-16

5. Hematopoietic stem/progenitor cells are less prone to undergo apoptosis than lymphocytes despite similar DNA damage response;Oncotarget;2017-03-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3